XML 20 R10.htm IDEA: XBRL DOCUMENT
v3.23.1

INTANGIBLE ASSETS | 3 Months Ended
--- | ---
Mar. 31, 2023
INTANGIBLE ASSETS [Abstract] |
INTANGIBLE ASSETS |
4. | INTANGIBLE ASSETS
Intangible assets at March 31, 2023 and December 31, 2022 consist of the following:
|  | March 31, 2023 |  |  | December 31, 2022 |
|  |  |  |  | Accumulated |  |  |  |  |  |  |  |  | Accumulated |  |  |  |
|  | Cost |  |  | Amortization |  |  | Net |  |  | Cost |  |  | Amortization |  |  | Net |
Trademark and other intangible rights related to Nabi-HB |  | $ | 4,100,046 |  |  | $ | 3,416,706 |  |  | $ | 683,340 |  |  | $ | 4,100,046 |  |  | $ | 3,270,276 |  |  | $ | 829,770 |
Rights to intermediates |  |  | 907,421 |  |  |  | 756,184 |  |  |  | 151,237 |  |  |  | 907,421 |  |  |  | 723,776 |  |  |  | 183,645 |
|  | $ | 5,007,467 |  |  | $ | 4,172,890 |  |  | $ | 834,577 |  |  | $ | 5,007,467 |  |  | $ | 3,994,052 |  |  | $ | 1,013,415 |
All of the Company’s intangible assets were acquired in the Biotest Transaction. Amortization expense related to these intangible assets was $0.2 million for the three months ended March 31, 2023 and 2022. Estimated future aggregate amortization expense is expected to be as follows:
Remainder of 2023 |  | $ | 536,514 |
2024 |  |  | 298,063 |

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for all or part of the information related to intangible assets. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -URI https://asc.fasb.org/subtopic&trid=2144471 + Details
Name: | us-gaap_IntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration